Form D · Pharmaceuticals
Pelage Pharmaceuticals, Inc.
Los Angeles, CA · CIK 0001982875
Offering snapshot reported Nov 24, 2025 · SEC filing
- Reported sold
- $120M Offering amount: $120M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 18, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 24, 2025 | Initial | $119,999,987 | No comparison | 5 | SEC filing |
| Aug 23, 2024 | Initial | $13,999,994 | No comparison | 6 | SEC filing |
| Jun 28, 2023 | Initial | $16,749,994 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-564886
Source: Form D, filed Nov 24, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Heather Christofk | Executive |
| Cathy Friedman | Director |
| Daniel Gil | Director, Executive |
| Richard Heyman | Director |
| William Edward Lowry | Director, Executive |
| Christina Weng | Executive |
| Nathan Wheeler | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
907 Westwood Blvd #384
Los Angeles, CA, 90024
Phone: 949-244-9904
Los Angeles, CA, 90024
Phone: 949-244-9904